According to a new report, published by KBV research, The Global Vitrification Market size is expected to reach $24.1 billion by 2030, rising at a market growth of 17.2% CAGR during the forecast period.
The Oocytes segment is leading the Global Vitrification Market, By Specimen in 2022; thereby, achieving a market value of $10.4 billion by 2030. A growing public awareness of oocyte preservation and favorable government policies are responsible for the segment's substantial revenue share. Oocyte preservation has become a legal practice in recent years owing to efforts made by governments worldwide. A functional ART approach is the vitrification of oocytes in egg banks.
The Biobanks segment would exhibit a CAGR of 18.1% during (2023 - 2030). The cryobank of eggs, embryos, and sperm has substantially expanded since the advent of vitrification technology, replacing the slow freezing of biospecimen. The existence of numerous biobanks has accelerated the process of egg donation. The banks offer databases of egg donors, allowing those seeking IVF with donated eggs to make educated choices. The revenue share of biobanks in the market is anticipated to rise.
The Europe region dominated the Global Vitrification Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $8.6 billion by 2030. The North America region is poised to grow at a CAGR of 16.8% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 18.1% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/vitrification-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitüb GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech.
By Specimen
By End-use
By Geography
Companies Profiled
Unique Offerings 
